BLAINJECTIONINJECTABLE
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEMGLEE is a biosimilar insulin glargine (YFGN) approved as an injectable insulin analog for diabetes management. It is a follow-on biologic referencing Lantus and is used for glycemic control in patients with type 1 and type 2 diabetes. The product works by mimicking endogenous insulin to regulate blood glucose through subcutaneous injection.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30), suggesting stable demand but intensifying market competition that may constrain team expansion.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SEMGLEE offers exposure to the competitive biosimilar market and payer negotiation strategy within Viatris' established diabetes franchise. Career growth potential is moderate given the product's peak lifecycle status and market saturation, with emphasis on commercial execution over innovation.
Brand ManagerField Sales Representative
Worked on SEMGLEE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.